Evidence map›Paper›PMID 40884630›Full record

Trial reportClinical oral investigations2025

Impact of systemic resveratrol on non-surgical periodontal treatment of smokers: A 12-month randomized clinical trial.

Vanessa Haguihara Lucchesi, Ana Paula Oliveira Giorgetti, Mônica Grazieli Corrêa, Vanessa G A Pecorari, Bruno Braga Benatti, Howard C Tenenbaum, Fabiano Ribeiro Cirano, Suzana Peres Pimentel, Márcio Zafallon Casati

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Clinical oral investigations, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Vanessa Haguihara LucchesiDental Research Division, Scholl of Dentistry, Universidade Paulista (UNIP), São Paulo, São Paulo, Brazil.
Ana Paula Oliveira GiorgettiDental Research Division, Scholl of Dentistry, Universidade Paulista (UNIP), São Paulo, São Paulo, Brazil.
Mônica Grazieli CorrêaDental Research Division, Scholl of Dentistry, Universidade Paulista (UNIP), São Paulo, São Paulo, Brazil.
Vanessa G A PecorariDental Research Division, Biostatistcs Department, Scholl of Dentistry, Universidade Paulista (UNIP), São Paulo, São Paulo, Brazil.
Bruno Braga BenattiSchool of Dentistry, Federal University of Maranhão, São Luís, MA, Brazil.
Howard C TenenbaumDepartment of Periodontology, Faculty of Dentistry and Laboratory Medicine and Pathobiology, Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
Fabiano Ribeiro CiranoDental Research Division, Scholl of Dentistry, Universidade Paulista (UNIP), São Paulo, São Paulo, Brazil.
Suzana Peres PimentelDental Research Division, Scholl of Dentistry, Universidade Paulista (UNIP), São Paulo, São Paulo, Brazil.
Márcio Zafallon CasatiDepto de Odontologia, Universidade Paulista - UNIP, Av. Dr. Bacelar, 1212, 4o andar, Vila Clementino, São Paulo, 04026-002, SP, Brazil. mzcasati@gmail.com.

Funding

The National Council for Scientific and Technological Development 301563/2017-9
6 · The paper itself

Abstract

objectiveSmoking patients demonstrate an elevated risk of periodontitis development and respond poorly to periodontal therapy as compared to nonsmokers, and resveratrol (RSV) demonstrated a positive effect in the reduction of periodontitis progression in both animal and clinical trials. However, to the authors' knowledge, no clinical study has assessed the impact of resveratrol under smoking conditions. Thus, this trial aimed to evaluate the effect of systemic administration (SA) of RSV adjunct to full-mouth ultrasonic debridement (FMUD) of periodontitis smoking patients (PSP). MATERIALS AND

methodsThirty-eight individuals were randomly assigned to two groups:Placebo ( n = 19) -FMUD and placebo for 180 days; RSV ( n = 19) FMUD and RSV (500 mg/day) for 180 days. Clinical and immunoinflammatory outcomes were assessed at baseline, 3-, 6-, and 12-months post-therapy, and microbiological outcomes were evaluated at baseline, 3-, 6- months post-therapy.

resultsRSV appeared to induce lower PD [2.96 (0.41) - 3 months; 2.85 (0.40) - 6 months; 2.80 (0.35)- 12 months], CAL [4.02 (0.90) - 3 months; 4.04 (0.81) - 6 months; 3.87 (0.78) - 12 months], and PMG [2.20 (0.56) - 3 months; 2.28 (1.14) - 6 months; 2.32 (3.27) - 12 months] readings as compared to Placebo [PD: 3.22 (0.51) - 3 months; 3.07 (0.42) - 6 months; 3.02 (0.42) - 12 months; CAL: 4.43 (0.99) - 3 months; 4.24 ((0.89) - 6 months; 4.39 (0.93) - 12 months; PMG: 2.50 (0.50) - 3 months; 2.53 (0.45) - 6 months; 2.67 (0.46) - 12 months] throughout the time (p < 0.05). The concentration of Aggregatibacter actinomycetemcomitans (Aa) was significantly higher in moderate [2.29 (1.10); 1.61 (1.02) for PL and RSV, respectively] and deep PD [2.39 (1.14); 1.73 (0.90) for PL and RSV respectively] at 3 months for the Placebo group (p < 0.05). Additionally, Aa levels were lower at 6 months in the deep sites for the RSV group (p < 0.05) [1.77 (0.94); 2.23 (1.08) for PL and RSV, respectively]. Immunoinflammatory analysis showed lower levels of IL-1β at 3-month periods in deep sites in the RSV group [92.6 ± 84.2; 35.36 (52.92) for PL and RSV, respectively] and lower concentrations of IL-6 in the RSV group at 3 and 12 months in both moderate [8.11 (9.50); 4.67 (4.20) - 3 months for PL and RSV, respectively; 8.01 ± 3.52; 5.33 (4.14) - 12 months for PL and RSV, respectively]; and deep sites [4.69 (3.06); 3.57 (3.73) - 3 months for PL and RSV, respectively]; 3.50 (2.67); 2.10 (0.89) - 12 months for PL and RSV, respectively] (p < 0.05).

conclusionIn conclusion, systemic administration of RSV improves clinical results and modulates IL-1β at 3 months, IL-6 at 3- and 6- months, in deep sites of smoking patients when associated with FMUD.

trial registrationRebec identifier https//ensaiosclinicos.gov.br/rg/RBR3gt65c.

Indexed as

PeriodontitisResveratrolSmokingAdultDouble-Blind MethodFemaleHumansMaleMiddle AgedPeriodontal DebridementSmokersTreatment OutcomeUltrasonic TherapyResveratrolPeriodontal debridement.PeriodontitisResveratrolSmoking

Identifiers

PMID40884630

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.